according to type or class of anti-TNF, disease subgroups, duration or use of synthetic drugs and prednisone. Four (36.3%) cases occurred in the first year, median 5.3 (1.2-8.8) months after initiating anti-TNF exposure, 2 of them (50%) in patients with positive LTBI. Seven cases were probably due to re-exposure since occurred later, median 21.9 (14.2-42.8) months (5 in patients with negative LTBI screening). Six patients (54.5%) re-initiated treatment with ETA. Only the patient who developed pulmonary TB under ETA had a second TB infection after 18 months of therapy.

Conclusion: Despite the adequate screening and treatment of LTBI, according to local guidelines, TB still occurs in spondyloarthritis patients under anti-TNF therapy, even in the first year of treatment. These data point to LTBI screening/treatment failure, maybe due to anergy, mainly in PsA patients, with peripheral disease, low adherence or re-exposition in an endemic environment. The high frequency of extrapulmonary disease is also a diagnostic challenge.

REFERENCES

- [1] Cantini F, Nannini C, Niccoli L, et al; SAFEPIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. *Autoimmun Rev*. 2015 Jun;14(6):503-9.

Disclosure of Interests: Andrea Shimabuco: None declared, Ana Medeiros: None declared, Renata Miossi: None declared, Karina Bonfiglioli Speakers bureau: Has received speaking fees from Roche, Pfizer, Bristol-Myers Squibb, Abbvie and Janssen., Julio Moraes: None declared, Celio Gonçalves: None declared, Percival D. Sampaio-Barros: None declared, Claudia Goldenstein-Schainberg: None declared, Fernando Souza: None declared, Leandro Prado: None declared, Michelle Lopes: None declared, Eloisa Bonfa: None declared, Carla Saad: None declared

DOI: 10.1136/annrheumdis-2019-eular.7062

AB0708

INFLUENCE OF IMMUNOGENICITY ON LONG-TERM MAINTENANCE OF ADALIMUMAB IN SPONDYLOARTHRITIS

Marine Samain^{1,2}, Emilie Ducourau^{1,2,3}, Theo Rispens⁴, Emmanuelle Derris⁵, Fabienne Le Guilhard⁶, Lucia Andras⁶, Aleth Perdriger⁷, Eric Lespessailles³, Antoine Martin⁸, Grégoire Cormier⁹, Thomas Armingeat¹⁰, Valerie Devauchelle-Pensec^{11,12}, Elisabeth Gervais¹³, Benoit Le Goff¹⁴, Annick de Vries¹⁵, Eric Piver^{16,17}, Gilles Paintaud^{2,18}, Céline Desvignes^{2,18}, David Ternant^{2,18}, Hervé Watier^{2,19}, ^{1,2}Philippe Goupille²⁰, Denis Mulleman^{1,2}. This work was a collaborative venture by the VICTOR HUGO network (Hôpitaux Universitaires du Grand Ouest—Western France University Hospitals; <http://www.srouest.fr>), dedicated to innovative research on rheumatic diseases. ¹CHRU de Tours, Service de Rhumatologie, Tours, France; ²University of Tours, EA 7501 GICC, Tours, France; ³CHU d'Orléans, Service de Rhumatologie, Orléans, France; ⁴Landsteiner laboratories, Sanquin Research, Amsterdam, Netherlands; ⁵CHU de Mans, Service de Rhumatologie, Le Mans, France; ⁶CHU de Blois, Service de Rhumatologie, Blois, France; ⁷CHRU de Rennes, Service de Rhumatologie, Rennes, France; ⁸CHU de Saint-Brieuc, Service de Rhumatologie, Saint-Brieuc, France; ⁹CHU Vendée, Service de Rhumatologie, La Roche-sur-Yon, France; ¹⁰CHU de Saint-Nazaire, Service de Rhumatologie, Saint-Nazaire, France; ¹¹Université de Brest, Inserm UMR1227 LBAI, Brest, France; ¹²CHRU de Brest, Service de Rhumatologie, Brest, France; ¹³CHRU de Poitiers, Service de Rhumatologie, Poitiers, France; ¹⁴CHRU de Nantes, Service de Rhumatologie, Nantes, France; ¹⁵Biologicals Lab, Sanquin Diagnostic Services, Amsterdam, Netherlands; ¹⁶University of Tours, Inserm U 1259, Tours, France; ¹⁷CHRU de Tours, Laboratoire de Biochimie, Tours, France; ¹⁸CHRU de Tours, Laboratoire de Pharmacologie-Toxicologie, Tours, France; ¹⁹CHRU de Tours, Laboratoire d'Immunologie, Tours, France; ²⁰CHRU de Tours, Inserm CIC1415, Tours, France

Background: Immunogenicity of anti TNF monoclonal antibodies leads to poor or secondary loss of response. Methotrexate reduces anti-drug antibodies (ADA) to adalimumab at week 26 in spondyloarthritis (SpA).¹

Objectives: Herein we sought to examine adalimumab long term persistence in ADA positive versus ADA negative SpA patients.

Methods: The CoMARIS study (Combination of Methotrexate and Adalimumab to Reduce Immunization in patients with axial SpA) is a 26-week prospective, randomised, open-labelled, multicentre study in which patients received adalimumab 40 mg subcutaneously (s.c.) every other week either in combination with MTX 10 mg s.c. for 26 weeks or without MTX. In a post hoc analysis, we reviewed the charts of patients to

assess adalimumab persistence. A Cox model analysis was performed to test the following covariates: MTX combination or not, sex, presence of ADA at week 26.

Results:

Data from 104 patients (54 without MTX and 50 with MTX) were reviewed, and time of adalimumab discontinuation was collected. The median time of follow-up was 210.57 weeks. ADA positivity at week 26 was the only covariate associated with adalimumab persistence. The median retention rate of adalimumab in ADA positive patients was 56.9 weeks, as compared with 98.6 weeks in those without ADA (log rank: $p=0.015$). In the Cox model analysis, the presence of ADA at week 26 increased the risk of adalimumab discontinuation by 1.78 [IC 95%=1.11-2.85], $p=0.016$.

Adalimumab retention rates in function of ADA status at 26 weeks

Figure. adalimumab retention rate in ADA positive patients (n=38) at week 26 versus ADA negative patients (n=66), log rank: $p=0.015$

Conclusion: Immunogenicity is a key factor that contributes to adalimumab discontinuation in SpA. MTX at initiation may therefore be considered in combination to adalimumab in SpA patients.

REFERENCES

- [1] Ducourau E, et al. Methotrexate reduces adalimumab immunogenicity in patients with spondyloarthritis: a randomized clinical trial. *EULAR17-1527*.

Acknowledgement: This work was promoted by the Regional University Hospital Center of Tours and supported by grants from the French Ministry for Health and Sport within the framework of the Programme Hospitalier de Recherche Clinique2011.

Disclosure of Interests: Marine Samain: None declared, Emilie Ducourau Speakers bureau: BMS and Abbvie, Theo Rispens Grant/research support from: Genmab, Speakers bureau: Pfizer, Abbvie, Regeneron, Emmanuelle Derris: None declared, Fabienne Le Guilhard: None declared, Lucia Andras: None declared, Aleth Perdriger: None declared, Eric Lespessailles Grant/research support from: Grants/research support from Amgen, Eli Lilly, MSD, UCB., Consultant for: Consultant for Amgen, Expanscience, Eli Lilly, MSD, UCB., Antoine Martin: None declared, Grégoire Cormier: None declared, Thomas Armingeat: None declared, Valerie Devauchelle-Pensec Grant/research support from: Roche-Chugai, Speakers bureau: MSD, BMS, UCB, Roche, Elisabeth Gervais Speakers bureau: Abbvie, BMS, MSD, Pfizer, Roche, UCB, Novartis, Benoit Le Goff Speakers bureau: Abbvie, BMS, Janssen, MSD, Pfizer, Sanofi-Genzyme, UCB, Novartis, Annick de Vries: None declared, Eric Piver: None declared, Gilles Paintaud Grant/research support from: Novartis, Roche Pharma, Sanofi-Genzyme, Chugai, Pfizer and Shire, Céline Desvignes: None declared, David Ternant Speakers bureau: Sanofi, Amgen, Hervé Watier: None declared, Philippe Goupille Grant/research support from: Financial compensation received from MSD on a pro-rotas basis for participation in Scientific Committee meetings and functions for this study, Speakers bureau: Abbvie, Biogaran, BMS, Hospira, Janssen, MSD, Pfizer, Sanofi-Genzyme, UCB, Denis Mulleman Speakers bureau: Pfizer, Novartis, Grifols

DOI: 10.1136/annrheumdis-2019-eular.4698